
    
      Older patients with esophageal cancer have been correlated with poor prognosis because of
      having little chance to receive aggressive local therapy, including concurrent
      chemoradiotherapy. In this phase II trial, the efficacy and toxicity of S-1 with concurrent
      radiotherapy will be investigated in this setting.
    
  